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ABSTRACT 
Background: Vulvovaginal candidiasis (VVC) is a fungal infection of the vagina and vulva. It is usually caused by 
Candida albicans, however, occasionally other candida species are responsible. The optimal treatment of VVC has not 
yet been defined. The present study was designed to compare the efficacy and safety of a single oral dose of fluconazole 
with clotrimazole vaginal cream as the treatment of choice for recurrent VVC. 
Materials and methods: We conducted a clinical trial study on 124 women with RVVC. Sampling of vaginal discharge 
was achieved for clinically suspected patients, then, observed with KOH for vaginal candidiasis. Sample culture was 
performed for cases in whom the result of direct examination was negative but there was high clinical suspicion of the 
disease. For laboratory examination, swab specimens were placed on sabourauds agar plus chloramphenicol and 
cyclohexamide with natural PH. For treatment, patients were randomized systematically in 2 equal groups, one receiving 
clotrimazole vaginal cream 5g/day for 7 days for acute episode and 5g twice a week for 6 months as a prophylaxis. The 
second group was prescribed single oral dose of fluconazole capsule 150 mg for acute episode followed by prophylactic 
regimen of 150 mg weekly for 6 months. 
Results: A total of 124 women with RVVC were enrolled and assigned in 2 groups of fluconazole and clotrimazole with 
the mean age of 32±5 years (a range, 18-50 years) and 32±2 years (a range, 19-49 years), respectively. Of 117 cases, the 
recurrence rate was 8.6% in fluconazole and 8.5% in clotrimazole group. Recurrence rate in follow up period (second 6 
months) was 38.3% and 40%, respectively (NS). 
Conclusion: Response to treatment and reduction in recurrence rate of VVC were similar among fluconazole and long-
term users of azole vaginal creams.  
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INTRODUCTION  
1Vulvovaginal candidiasis (VVC) is a fungal 
infection of the vagina and vulva. An estimated of 
75% of all women experience at least one episode 
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of VVC in their lifetime, of whom one half will 
experience a recurrence (1). Recurrent 
vulvovaginal candidiasis (RVVC) is defined as ≥ 4 
episodes of symptomatic VVC each year (2). 
VVC is usually caused by Candida albicans, 
however, occasionally other candida species are 
responsible. C. albicans is responsible for 35%- 
90% of vaginal yeast infections. RVVC is caused 
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by the persistence of a single yeast genotype that 
undergoes morphological and behavioral changes 
in the presence of antifungal agents (3). Associated 
symptoms and signs include pruritus, burning, 
soreness, abnormal vaginal discharge, dysparonia, 
and vaginal and vulvar erythema and edema (4).  
Known predisposing host factors which include 
uncontrolled diabetes mellitus, 
immunosuppression, pregnancy, and hormone 
replacement therapy, could partly explain RVVC. 
Broad spectrum antibiotic use has been suggested 
as a risk factor for both acute and recurrent VVC. 
Frequent recurrences of symptomatic 
vulvovaginitis result in considerable suffering and 
have a markedly negative influence on sexual 
relation (5). 
The diagnosis should be confirmed by physical 
examination, direct microscopy of the vaginal 
secretions and, of course, fungal culture. 
Characteristic budding mycelia are seen in fewer 
than 30% of positive candida cultures (6).  
The optimal treatment of VVC has not yet been 
defined (7). Consequently, treatment must be 
individualized based on a comparison of 
effectiveness, convenience, potential side effects, 
and costs. Treatment of the acute episode usually 
involves topical application of Azoles drugs or 
nystatin or systemic oral antifungal agents. 
However, for recurrent VVC, after treatment of the 
acute episode, subsequent prophylaxis 
(maintenance therapy) is essential (7). Several 
maintenance regimens have been proposed, like 
ketoconazole 100 mg/day or fluconazole 150mg 
weekly for 6 months (7). Oral treatment carries a 
greater potential for systemic toxicity and drug 
interaction for pregnant women, diabetic patients, 
and for whom it is contraindicated (such as those 
with renal or hepatic insufficiency).   
The present study was designed to compare the 
efficacy and safety of a single oral dose of 
fluconazole (150mg) weekly with clotrimazole 
vaginal cream 150 mg twice weekly for 6 months 
as the treatment of choice for recurrent VVC.  
PATIENTS and METHODS 
We conducted a clinical trial study on 124 
women with RVVC. Cases were recruited from 
patients presenting to the Gynecology and 
Obstetrics Clinic at Tabriz Medical University 
between 2002–2004.  
Patients with signs and symptoms of candidia 
vulvovaginitis (pruritus, irritation, burning, 
discharge, erythema and edema) and a history of 
more than 4 episodes of VVC during the past year 
(at least one of the previous episodes must have 
been diagnosed by physician) were included. The 
following exclusion criteria were applied at 
baseline: severe chronic disease, use of oral 
hypoglycemic drugs, chronic dermatologic disease.  
All subjects were requested to sign an informed 
consent, then, social, demographic and medical 
features as well as the present complaint of the 
patient were inquired and vaginal examination was 
performed. 
Sampling of vaginal discharge was achieved for 
clinically suspected patients, then, observed with 
KOH for vaginal candidiasis. Sample culture was 
performed for cases in whom the result of direct 
examination was negative but there was high 
clinical suspicion of the disease. For laboratory 
examination, swab specimens were placed on 
sabourauds agar plus chloramphenicol and 
cyclohexamide with natural PH. The specimens 
were stored at 37°C and subsequently identified by 
smooth white colony formation. FBS (fasting blood 
sugar) test was requested to confirm the unknown 
diabetes mellitus, and Pap smear was also 
performed to rule out pre-cancer lesion of the 
cervix.  
For treatment, patients were randomized 
systematically in 2 groups with 62 cases in each. 
The first group received clotrimazole vaginal 
cream 5g/day for 7 days for acute episode and 5g 
twice a week for 6 months as a prophylaxis. The 
second group was prescribed single oral dose of 
fluconazole capsule 150 mg for acute episode 
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followed by prophylactic regimen of 150 mg 
weekly for 6 months.  
Patients were visited a week following the 
initiation of therapy and then monthly for one year.  
At each visit, a detailed clinical history was 
inquired, a pelvic examination was performed, and 
a vaginal sample was obtained for microscopic 
examination. Patients had to discontinue the 
assigned study treatment if they had severe 
complication, missed two or more consecutive 
doses of the drug or had irregular control visits. 
The recurrence of VVC was determined by patient 
complaint, physical examination, and laboratory 
finding (microscopic findings or fungal culture). 
Patients' satisfaction with drug use was evaluated 
by interview using a Likert spectrum. 
Data were analyzed by SPSS for Windows 
(version 10.5, USA) and Mann-Withney U-test, 
Kaplan-Mayer method and chi-square test were 
used, when appropriate.  
 
RESULTS 
A total of 124 women with RVVC were 
enrolled and assigned in 2 groups of fluconazole 
and clotrimazole with the mean age of 32±5 years 
(a range, 18-50 years) and 32±2 years (a range, 19-
49 years), respectively. The main socio-
demographic characteristics of patients are 
presented in table 1. These variables showed no 
significant difference between the two groups. 
As shown in table 2, the frequency of antibiotic 
use in the past 6 months, contraception method, the 
history of diabetes, and results of laboratory 
findings were more or less the same in both groups. 
None of the patient was pregnant. 
The main symptoms of disease were vaginal 
burning (82.3%), and vaginal pruritus (78.2%), 
however, vulvovaginal erythema (87.9%), mucosal 
edema (79.8%), and white caseouse discharge 
(68.5%) were more commonly found during 
physical examination. Having followed the 
prescribed regimens, the cure rate at first visit was 
99%. 
 
Table 1. Sociodemographic characteristics of patients 
with Vulvovaginal candidiasis  
Group*  
Clotrimazole 
(n=59) 
Fluconazole 
(n=58) 
Literature status 
Illiterate 32(54.2) 26(44.8) 
Diploma 21(35.5) 23(39.6) 
Graduated 6(10.3) 9(15.6) 
Occupation 
Housekeeper 44(74.6) 44(76.0) 
Employee 15(25.4) 14(24.0) 
* Groups showed no significant difference 
 
Table 2. Medical characteristics of patients with 
Vulvovaginal candidiasis 
Group*  
Clotrimazole 
(n=59) 
Fluconazole 
(n=58) 
Contraceptive method 
OCP 12(20.3) 18(31) 
IUD 9(15.2) 12(20.6) 
Barrier 5(8.5) 5(8.8) 
Withdrawal 33(56) 23(39.6) 
Antibiotic use during 
the last 6 months 
17(28) 15(25) 
Diabetes mellitus 6(10) 7(11.6) 
Laboratory results 
Direct smear with 
KOH 
55(91.6) 57(95) 
Candida culture 5(8.3) 3(5) 
Pap smear 
Normal 41(69.4) 35(60.3) 
Positive for candida  12(19) 8(13.8) 
Cervicitis 6(11.6) 15(25.9) 
* Groups showed no significant difference 
 
During the third visit, 2 patients of fluconazole 
group were excluded because of irregular visits 
while 2 other patients were excluded during the 4th 
and 5th visit because of more than 3 times missing 
drug use. On the other hand, in the clotrimazole 
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group, 3 patients were excluded in the 2nd and 3rd 
visit because of local sensitivity to the drug. 
Of remaining 117 cases, as presented in table 3, 
the recurrence rate was 8.6% in fluconazole group 
and 8.5% in clotrimazole group. Recurrence rate in 
follow up period (second 6 months) was 38.3% and 
40%, respectively (NS). 
 
Table 3. Recurrence rate of vulvovaginal candidiasis 
among the two groups during treatment and follow-up 
period 
Group*  
Clotrimazole 
(n=59) 
Fluconazole
(n=58) 
Treatment period (first 6 months)  
1-6 months 5(8.5) 5(8.6) 
Follow-up period  
7th month 3(5.1) 3(5.2) 
8th month 0 2(3.5) 
9th month 2(3.4) 3(5.2) 
10th month 5(8.5) 4(6.9) 
11th month 5(8.5) 5(8.6) 
12th month 5(8.5) 6(10.3) 
Total recurrence (during 
a 12-month period) 
25(42.4) 26(44.8) 
* Groups showed no significant difference 
 
Table 4. Quality of drug use and satisfaction in both 
groups 
Group*  
Clotrimazole 
(n=59) 
Fluconazole 
(n=58) 
Completion of regimen protocol 
Complete 55(93.2) 49(84.4) 
1 missing dose 3(5.0) 5(8.6) 
2 missing doses 1(1.8) 4(7.0) 
Patient's satisfaction 
Very good 19(32.2) 10(17.2) 
Good 15(25.4) 14(24.4) 
Relatively good 13(21.7) 9(15.5) 
Relatively bad 8(13.3) 9(15.5) 
Bad 2(3.3) 8(13.7) 
Very bad 2(3.3) 8(13.7) 
 
Totally, 88.8% of cases in fluconazole group 
and 85% of cases in clotrimazole group used their 
drug regularly. Drug usage missing rate (missed ≥2 
consecutive doses of the drug) was 4 cases in 
fluconazole and 9 cases in clotrimazole group, 
respectively. Local cream users were more satisfied 
with their regimen (p<0.003) (table 4).  
In fluconazole group, the main drug side effects 
were nausea (34.5%), and vomiting (6.9%), 
however, local sensitivity to drug (8.5%) was the 
only significant side effect. Systemic complications 
among cream users was significantly less than 
capsule users (P<0.004).  
 
DISCUSSION 
Our study showed that the most common 
complaints of patients were vaginal burning and 
pruritus which is compatible with the reported 
symptoms for vaginal candidiasis including vaginal 
discharge, burning and pruritus (8). The most 
prevalent signs in this study were white caseouse 
discharge and erythema. 
Direct observation of fungal mycelia by using 
KOH under light microscope is the simplest and 
the most available test for diagnosis of VVC (9). 
By adding 10% KOH to the slide, the epithelial 
cells undergo lysis, which increases the ability to 
identify hyphae or blastospores (10). Although 
microscopic evaluation is the best office tool to 
diagnose vulvovaginal candidiasis, it lacks 
accuracy, as demonstrated by data showing that up 
to 50% of patients with culture-proven 
symptomatic vulvovaginitis have negative 
microscopic findings. In our study, Sample culture 
was also performed for cases in whom the result of 
direct examination was negative but there was high 
clinical suspicion of the disease. In addition, a 
larger proportion of false-negative finding may 
result from cases of C. glabrata infections, possibly 
because of the lack of hyphae formation by this 
organism, which makes microscopic identification 
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more difficult (11). In our study, the rate of false-
negative finding of direct examination was 6.3% 
which was confirmed by fungal culture, indicating 
the test reliability.  
Broad spectrum antibiotic use, use of combined 
oral contraceptives, pregnancy, diabetes, 
immunosuppression, and hormone replacement 
therapy (12) are positively associated with 
symptomatic vulvovaginal candidiasis episodes (8). 
In our study, OCP use (12 cases), antibiotic use (33 
cases), and diabetes mellitus (13 cases) were the 
predisposing factors. In a case-control study over 
684 cases with symptomatic VVC and 901 controls 
(asymptomatic women), 19.3% of cases and 11.9% 
of controls were antibiotic users while VVC was 
revealed to be directly related with antibiotic use 
(13). Bohannon suggested that hyperglycemia is 
the major cause of increased susceptibility of 
diabetic patients to VVC. Increased glucose levels 
in genital tissues enhance yeast adhesion and 
growth. Beginning at levels of 10-11mmol/L (180-
196 mg/dl), hyperglycemia may impair several 
aspects of humoral host defense, resulting in 
decreased random motion of neutrophils, 
chemotaxis, phagocytosis, and microbial killing 
(11). In our study, because of small number of 
diabetic patients, the analysis of studied drug 
regimen effect on this disease is impossible, 
although, because of interaction between 
fluconazole and hypoglycemic drugs, use of 
vaginal clotrimazole with the same efficacy and 
lower side effects is recommended. 
Patel et al. suggested that clothing habits, 
personal hygiene, a history of bacterial vaginosis, 
consumption of acidophil-containing products, and 
age <40 years are other predisposing factors (1). 
Bear in mind their findings, in our study, only age 
<40 years (32±5) was found as a predisposing 
factor.  
Treatment of vaginal candidiasis usually 
involves topical application of polyene or azole 
compounds or systemic oral azoles. In a study by 
Sobel et al. on 429 patients with vaginal 
candidiasis, the efficacy and safety of a single oral 
dose of fluconazole was compared with a 7-day 
clotrimazole (100/mg) regimen. At day 14th, 
clinical cure or improvement was found in 94% of 
fluconazole- and 97% of clotrimazole-treated 
patients, however, after 35 days, 75% of both 
groups remained clinically cured, therefore, the 
cure rate was similar in both groups (14). 
In a double-blind study by Sadovsky, the 
treatment of acute episode of vaginal candidiasis 
by ٛ fluconazole in 2 divided doses within 2 hours 
was compared with fluconazole single dose 
therapy. In this study, the more cure rate achieved 
by divided doses, but because of popularity of 
single dose method, the authors reported that this 
method is more effective (15). Thus, patient’s 
acceptance of drug type and consumption route is 
of utmost importance.  
In conclusion, response to treatment and 
reduction in recurrence rate of VVC were similar 
among fluconazole and long-term users of azole 
vaginal creams. Furthermore, the local treatment 
has fewer side effects and is more satisfactory. We 
recommend periodic and long-term use of azole 
creams for treatment of RVVC in women who are 
pregnant or have any systemic problem. 
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